Improving Outcomes for Pediatric and Adult Patients with Immune Thrombocytopenia
Please use the box in the top-right corner of the screen to login or register.
Release Date: February 10, 2023
Expiration Date: February 10, 2024
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The overall goal of immune thrombocytopenia (ITP) treatment is to reduce platelet and megakaryocyte destruction via immune modulation or splenectomy, or to increase megakaryocyte platelet production via thrombopoietin receptor agents. To facilitate treatment decisions, it is critical that adult and pediatric clinicians are knowledgeable about ITP pathophysiology. In this activity, two experts will discuss pediatric and adult treatment options, guideline recommendations and evidence supporting best practice, and strategies for engaging in shared decision-making.
This activity is designed for clinicians who specialize in adult and pediatric hematology, as well as emergency room clinicians and hospitalists.
Upon completion of this educational activity, participants should be able to:
- Review the pathophysiology of ITP and the various mechanisms that can be targeted to treat this condition in adult and pediatric patients
- Apply current guideline recommendations for the treatment of pediatric and adult ITP, including the addition of recently approved agents, to practice
- Discuss emerging agents that are currently being developed for ITP and how these agents may be integrated into practice as each is approved
- Select ITP therapy that is designed to optimize long-term outcomes, patient preferences, and adherence
Improving Outcomes for Pediatric and Adult Patients with Immune Thrombocytopenia – Hanny Al-Samkari, MD and Michele P. Lambert, MD, MSTR
Instructions for Participation and Credit
This activity is eligible for credit through February 10, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Hanny Al-Samkari, MD
Classical Hematologist and Clinical Investigator
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Dr. Hanny Al-Samkari is an Assistant Professor of Medicine at Harvard Medical School and a Hematologist and Clinical Investigator in the Massachusetts General Hospital (MGH) Division of Hematology/Oncology. He also serves as Co-Director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence.
His clinical and research interests are in hemostasis and hemolysis, with concentrations in HHT, thrombocytopenias and hemolytic anemias. He is focused on developing novel therapeutics for these diseases and currently serves as PI for many clinical trials in these areas.
Michele P. Lambert, MD, MSTR
Medical Director, Special Coagulation Laboratory
Attending Physician, Division of Hematology
Children’s Hospital of Philadelphia
Dr. Michele Lambert received her undergraduate degree in Biology from Rensselaer Polytechnic Institute and attended medical school at Rutgers New Jersey Medical School. She did her residency in Pediatrics at St. Christopher’s Hospital for Children followed by a year as Chief Resident and then a Hematology/Oncology Fellowship at The Children’s Hospital of Philadelphia. Dr. Lambert is now an Associate Professor of Pediatrics in The Perelman School of Medicine at the UPENN and an Attending Physician, Division of Hematology at the Children’s Hospital of Philadelphia where she is the Medical Director of the Special Coagulation Laboratory and Co-Director of the Frontier Program in Immune Dysregulation as well as the Director of the Pediatric Platelet Disorder Program at CHOP. Her particular clinical interest is in the inherited and acquired platelet disorders and in the interplay between genetics and disease.
Her current research focuses on understanding the role of genetics in this space. She is a member of the ClinGen Hemostasis and Thrombosis Clinical Domain Working Group and a Co-Chair of the ClinGen Hemostasis and Thrombosis Hemostasis and Thrombosis Gene Curation Expert Panel as well as the current Chair of the Pediatric ITP Consortium of North America. By understanding the drivers of differences in biology in platelet disorders, Dr. Lambert hopes to develop targeted therapies to improve outcomes.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-005-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-005-162
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Hanny Al-Samkari has relevant financial relationships related to consulting from Agios, Inc. (now Servier Laboratories), argenx, Dova Pharmaceuticals, Inc. (now Sobi), Forma Therapeutics, Inc., Moderna, Inc., Novartis AG, Rigel Pharmaceuticals, Inc., and Sobi. He has received research grants from Agios, (now Servier), Amgen Inc., Dova (now Sobi), and Sobi.
Dr. Michele Lambert has relevant financial relationships related to consulting from argenx, Dova Pharmaceuticals, Inc. (now Sobi), Janssen Pharmaceuticals, Inc., Novartis AG, Principia Biopharma (now Sanofi), Rigel Pharmaceuticals, Inc., Sanofi, Shionogi Inc., and Sobi, as well as advisory activities from Dova (now Sobi), Octapharma USA, Inc., Principia (now Sanofi), Rigel, and Shionogi. She has received research grants from argenx, Dova (now Sobi), Octapharma, Principia (now Sanofi), Novartis, Rigel, and Sysmex.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding the content of this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from UCB, Inc.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.